{
    "id": 219,
    "name": "colon cancer",
    "source": "DOID",
    "definition": "A colorectal cancer that is located_in the colon. [url:http\\://www.cancer.gov/dictionary?CdrID=44237]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:219",
    "evidence": [
        {
            "id": 516,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sutent (sunitinib) induced apoptosis in colon cancer cells in culture and in cell line xenograft models (PMID: 22912816).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 306,
                    "pubMedId": 22912816,
                    "title": "The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22912816"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 628,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 demonstrated efficacy in promoting apoptosis of colon cancer cells harboring a PIK3CA mutation in culture (PMID: 22543857).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 361,
                    "pubMedId": 22543857,
                    "title": "Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22543857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 652,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Nexavar (sorafenib) in combination with Adrucil (fluorouracil) displayed safety and efficacy in advanced solid tumors, including colon cancer (PMID: 22232731).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1086,
                "therapyName": "Fluorouracil + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 305,
                    "pubMedId": 22232731,
                    "title": "Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22232731"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 657,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Depakene (valproic acid), in combination with Mitozytrex (mitomycin C), inhibited cell viability of colon cancer cells isolated from patients (PMID: 17024798).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1686,
                "therapyName": "Mitomycin C + Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 380,
                    "pubMedId": 17024798,
                    "title": "Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17024798"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 658,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zolinza (vorinostat) decreased the growth of colon tumors in mice, and this effect was enhanced by co-administration of Lipitor (atorvastatin) (PMID: 22161747).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 381,
                    "pubMedId": 22161747,
                    "title": "Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22161747"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 664,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinial study, Faridak (panobinostat) enhanced the cytotoxicity of TRAIL, tumor necrosis factor-related apoptosis-inducing ligand, in colon cancer cell lines (PMID: 21965751).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1080,
                "therapyName": "Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 383,
                    "pubMedId": 21965751,
                    "title": "Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21965751"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 668,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lenvima (lenvatinib) induced apoptosis and inhibited proliferation of colorectal cancer cells in culture (PMID: 24255582).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 388,
                    "pubMedId": 24255582,
                    "title": "Effects of tyrosine kinase inhibitor E7080 and eNOS inhibitor L-NIO on colorectal cancer alone and in combination.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24255582"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 684,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical studu, BKM120 alone failed to induce tumor regression in mouse xenograft models of Kras G13D mutant colorectal cancer (PMID: 24576621).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 362,
                    "pubMedId": 24576621,
                    "title": "Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24576621"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1020,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical trials, Sirolimus (rapamycin) was shown effective in reducing tumors in mouse models of familial adenomatous polyposis and colon cancer with APC deficient tumors (PMID: 18768809, PMID: 20080688).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 737,
                    "pubMedId": 18768809,
                    "title": "Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18768809"
                },
                {
                    "id": 738,
                    "pubMedId": 20080688,
                    "title": "Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20080688"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1024,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, cells deficient in Apc protein had increased sensitivity to Navelbine (vinorelbine) compared to wild-type cells, and Navelbine (vinorelbine) treament decreased adenoma size in an Apc-deficient mouse model (PMID: 22399804).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 1685,
                "therapyName": "Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 740,
                    "pubMedId": 22399804,
                    "title": "The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22399804"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1029,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) reduced the number of dextran sodium sulfate-induced tumors in an APC-deficient mouse model for colon cancer (PMID: 20811697).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 745,
                    "pubMedId": 20811697,
                    "title": "Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20811697"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1088,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combined treatment of DNA methyltransferase inhibitor decitabine and EGFR inhibitor gefitinib on EGFR wild-type colon cancer cell lines resulted in synergistic effects in inhibiting cell growth and migration (PMID: 24874286).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 1531,
                "therapyName": "Decitabine + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 822,
                    "pubMedId": 24874286,
                    "title": "Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24874286"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1089,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Decitabine, an DNA methyltransferase inhibitor, inhibited cell growth in colon cancer cell lines (PMID: 24874286).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 650,
                "therapyName": "Decitabine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 822,
                    "pubMedId": 24874286,
                    "title": "Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24874286"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1126,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775), in combination with the Chk1 inhibitor, PF-00477736, showed efficacy in various human cancer cell lines (breast, ovarian, colon, prostate), independently of p53 status (PMID: 22713237).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1566,
                "therapyName": "Adavosertib + PF-00477736",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 394,
                    "pubMedId": 22713237,
                    "title": "Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22713237"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1189,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) reduced human colon cancer cell line-induced angiogenesis and delayed tumor growth in colon cancer cell line xenograft models, with the highest delay corresponding to tumors with the highest VEGF-expression levels (PMID: 19528456).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 939,
                    "pubMedId": 19528456,
                    "title": "Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19528456"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1241,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torisel (temsirolimus) increased sensitivity to Erbitux (cetuximab) in cell line xenograft models of colon cancer (PMID: 24493623).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1671,
                "therapyName": "Cetuximab + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 197,
                    "pubMedId": 24493623,
                    "title": "Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24493623"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1304,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) inhibited epithelial-mesenchymal transition, motility, and invasiveness in colon cancer cells lacking FBXW7 in culture (PMID: 23558291)",
            "molecularProfile": {
                "id": 2397,
                "profileName": "FBXW7 loss"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 572,
                    "pubMedId": 23558291,
                    "title": "Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23558291"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1348,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 inhibited phosphorylation of FGFR4 and increased sensitivity of colon cancer cell lines to Adrucil (fluorouracil), resulting in increased apoptosis in culture (PMID: 24503538).",
            "molecularProfile": {
                "id": 2409,
                "profileName": "FGFR4 over exp"
            },
            "therapy": {
                "id": 5255,
                "therapyName": "BGJ398 + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1057,
                    "pubMedId": 24503538,
                    "title": "Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24503538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1467,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the GLI1/GLI2 inhibitor, GANT61, resulted in cytotoxicity in colon cancer cell lines (PMID: 21135115).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1337,
                    "pubMedId": 21135115,
                    "title": "Hedgehog signaling drives cellular survival in human colon carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21135115"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1616,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "RAD54B knockout colon cancer cells demonstrated increased sensitivity to DNA damaging agents in cell culture compared to RAD54B wild-type cells, suggesting that RAD54B may be a potential therapeutic target for sensitization to chemotherapeutics (PMID: 25384516).",
            "molecularProfile": {
                "id": 2757,
                "profileName": "RAD54B wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1675,
                    "pubMedId": 25384516,
                    "title": "Rad54B serves as a scaffold in the DNA damage response that limits checkpoint strength.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25384516"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1717,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CGP049090 inhibited proliferation of a colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2082,
                "therapyName": "CGP049090",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1950,
                    "pubMedId": 14749129,
                    "title": "Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/14749129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1722,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ICG-001 decreased cell proliferation in colon cancer cell lines and in mouse models carrying APC inactivating mutations (PMID: 15314234).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2084,
                "therapyName": "ICG-001",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1915,
                    "pubMedId": 15314234,
                    "title": "A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15314234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1723,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mouse models of colon cancer carrying an APC 716del mutation had reduced polyp formation after treatment with MF tricyclic (PMID: 23843721).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2089,
                "therapyName": "MF tricyclic",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1954,
                    "pubMedId": 23843721,
                    "title": "Recent progress in mouse models for tumor suppressor genes and its implications in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23843721"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1726,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PKF115-584 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2081,
                "therapyName": "PKF115-584",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1950,
                    "pubMedId": 14749129,
                    "title": "Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/14749129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1729,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, StAx-35 inhibited proliferation of colon cancer cell lines carrying APC deletions in culture (PMID: 23071338).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2085,
                "therapyName": "StAx-35",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1916,
                    "pubMedId": 23071338,
                    "title": "Inhibition of oncogenic Wnt signaling through direct targeting of \u03b2-catenin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23071338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1734,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Y15 treatment increased apoptosis and decreased growth of colon cancer cells in culture (PMID: 23792569).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2088,
                "therapyName": "Y15",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1959,
                    "pubMedId": 23792569,
                    "title": "Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23792569"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1782,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 demonstrated antitumor activity against BRAF V600E colon cancer cell line xenografts (PMID: 16273091).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2074,
                    "pubMedId": 16273091,
                    "title": "BRAF mutation predicts sensitivity to MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16273091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1791,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 inhibited growth of TP53 wild-type colon cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1886,
                    "pubMedId": 25145672,
                    "title": "SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25145672"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1798,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Enzastaurin (LY317615) demonstrated efficacy by suppressing proliferation of cultured cells and growth in cell line xenograft models of colon cancer (PMID: 16103100).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1682,
                "therapyName": "Enzastaurin",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2084,
                    "pubMedId": 16103100,
                    "title": "The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16103100"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1960,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) is not indicated for use in colon cancer patients with NRAS exon 2 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 27389,
                "profileName": "NRAS exon2"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1961,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 2 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 27389,
                "profileName": "NRAS exon2"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1963,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial that supported FDA approval, the combination of Avastin (bevacizumab) and FOLFIRI chemotherapy demonstrated increased duration of overall survival and improved progression-free survival compared to FOLFIRI alone in patients with metastatic colorectal cancer (PMID: 22477726, PMID: 15175435).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2181,
                "therapyName": "Bevacizumab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Bevacizumab + FOLFIRI"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2416,
                    "pubMedId": 15175435,
                    "title": "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15175435"
                },
                {
                    "id": 2417,
                    "pubMedId": 22477726,
                    "title": "Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22477726"
                },
                {
                    "id": 15584,
                    "pubMedId": null,
                    "title": "Avastin (bevacizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2200,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AP 11014 inhibited Tgfb1 secretion, proliferation, and migration in colon cancer cells over expressing Tgfb1 (J Clin Oncol July 2004 vol. 22 no. 14_suppl 3132).",
            "molecularProfile": {
                "id": 6274,
                "profileName": "TGFB1 over exp"
            },
            "therapy": {
                "id": 2706,
                "therapyName": "AP 11014",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2757,
                    "pubMedId": null,
                    "title": "The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies",
                    "url": "http://meeting.ascopubs.org/cgi/content/short/22/14_suppl/3132"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2722,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Aliqopa (copanlisib) inhibited tumor growth in xenograft models of a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 24170767).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 245,
                    "pubMedId": 24170767,
                    "title": "BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24170767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2745,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PWT33597 decreased signaling of mTOR and PIK3 pathways in colon cancer cells with Pik3ca mutations (Cancer Res 2011;71(8 Suppl):Abstract nr 4485).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 880,
                "therapyName": "PWT33597",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3450,
                    "pubMedId": null,
                    "title": "Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR",
                    "url": "http://cancerres.aacrjournals.org/content/71/8_Supplement/4485.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2779,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring PIK3CA and KRAS mutations demonstrated sensitivity to AT13148 in culture (PMID: 22781553).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 3653,
                "therapyName": "AT13148",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 204,
                    "pubMedId": 22781553,
                    "title": "AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22781553"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2836,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R mutations (PMID: 21558396).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2840,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 inhibited growth and induced apoptosis in a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 22693356).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1018,
                    "pubMedId": 22693356,
                    "title": "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22693356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2848,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torin 1 inhibited cell proliferation of colon cancer cell cultures and patient-derived xenograft models (PMID: 24185040).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2247,
                "therapyName": "Torin 1",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3503,
                    "pubMedId": 24185040,
                    "title": "Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24185040"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2855,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, GDC-0980 delayed tumor growth in colon cancer cell line xenograft models harboring KRAS and PIKC3A mutations (PMID: 21998291).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 750,
                "therapyName": "GDC-0980",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3508,
                    "pubMedId": 21998291,
                    "title": "GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21998291"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2856,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Gedatolisib (PF-05212384) and PD-0325901 inhibited tumor growth in colon cancer cell line xenograft models harboring KRAS G13D and PIK3CA H1047R (PMID: 21325073).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 3025,
                "therapyName": "Gedatolisib + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2859,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AT-7867 inhibited proliferation of cultured HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations (PMID: 20423992, PMID: 24978597).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 2447,
                "therapyName": "AT-7867",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 962,
                    "pubMedId": 24978597,
                    "title": "Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24978597"
                },
                {
                    "id": 2290,
                    "pubMedId": 20423992,
                    "title": "AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20423992"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2864,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-443654 inhibited proliferation of colon cancer cell lines that have been reported to harbor KRAS and PIK3CA mutations in culture (PMID: 24569089, PMID: 24978597).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 2448,
                "therapyName": "A-443654",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 962,
                    "pubMedId": 24978597,
                    "title": "Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24978597"
                },
                {
                    "id": 3512,
                    "pubMedId": 24569089,
                    "title": "Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569089"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2876,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CC-223 inhibited proliferation of HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations, in culture (PMID: 25855786, PMID: 24978597).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 693,
                "therapyName": "CC-223",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 962,
                    "pubMedId": 24978597,
                    "title": "Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24978597"
                },
                {
                    "id": 3513,
                    "pubMedId": 25855786,
                    "title": "CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25855786"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3010,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 induced caspase activation in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 20570890, PMID: 22693356).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 843,
                    "pubMedId": 20570890,
                    "title": "Genomic and biological characterization of exon 4 KRAS mutations in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20570890"
                },
                {
                    "id": 1018,
                    "pubMedId": 22693356,
                    "title": "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22693356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3023,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vitrakvi (larotrectinib) inhibited cell growth, colony formation, Ntrk1 phosphorylation, and downstream signaling in a human colon cancer cell line harboring TPM3-NTRK1 in culture (PMID: 24162815).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3552,
                    "pubMedId": 24162815,
                    "title": "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3024,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lestaurtinib (CEP-701) inhibited cell growth, colony formation, Ntrk1 phosphorylation, and downstream signaling in a human colon cancer cell line harboring TPM3-NTRK1 in culture (PMID: 24162815).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 793,
                "therapyName": "Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3552,
                    "pubMedId": 24162815,
                    "title": "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3025,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited cell growth, colony formation, Ntrk1 phosphorylation and downstream signaling in a human colon cancer cell line harboring TPM3-NTRK1 in culture (PMID: 24162815).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3552,
                    "pubMedId": 24162815,
                    "title": "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3026,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NMS-P626 inhibited cell growth, Ntrk1 phosphorylation, and downstream signaling in a human colon cancer cell line harboring TPM3-NTRK1 in culture (PMID: 24962792).",
            "molecularProfile": {
                "id": 10688,
                "profileName": "TPM3 - NTRK1"
            },
            "therapy": {
                "id": 3044,
                "therapyName": "NMS-P626",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3485,
                    "pubMedId": 24962792,
                    "title": "The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24962792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3130,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited Braf V600E in vitro and inhibited growth of human colon cancer cells harboring BRAF V600E in culture (PMID: 21325073, PMID: 24042735).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 3639,
                    "pubMedId": 24042735,
                    "title": "Epigenetic and genetic features of 24 colon cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24042735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3131,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human colon cancer cells harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3132,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colon cancer cells harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 24042735).",
            "molecularProfile": {
                "id": 26186,
                "profileName": "KRAS G13D PIK3CA E545K PIK3CA D549N"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 3639,
                    "pubMedId": 24042735,
                    "title": "Epigenetic and genetic features of 24 colon cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24042735"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3146,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, iCRT-3 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2404,
                "therapyName": "iCRT-3",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3647,
                    "pubMedId": 21393571,
                    "title": "An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3149,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JW55 inhibited proliferation of colorectal cancer cells with an APC truncation mutation in culture and decreased tumor development in a mouse model expressing a conditional APC truncation mutation (PMID: 22440753).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2411,
                "therapyName": "JW55",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2223,
                    "pubMedId": 22440753,
                    "title": "A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22440753"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3151,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, iCRT-5 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2452,
                "therapyName": "iCRT-5",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3647,
                    "pubMedId": 21393571,
                    "title": "An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3152,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, iCRT-14 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture and decreased initial tumor growth in APC-mutant colon cancer cell line xenograft models (PMID: 21393571).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2453,
                "therapyName": "iCRT-14",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3647,
                    "pubMedId": 21393571,
                    "title": "An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3153,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G007-LK inhibited growth of APC-mutant colorectal cancer cell lines in culture and in xenograft models (PMID: 23539443).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3387,
                    "pubMedId": 23539443,
                    "title": "A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23539443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3261,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR-42 induced cell death in primary human colon cancer cells and cell lines in culture, and inhibited tumor growth in colon cancer cell line xenograft models (PMID: 26026677).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 987,
                "therapyName": "AR-42",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3701,
                    "pubMedId": 26026677,
                    "title": "The novel HDAC inhibitor AR-42-induced anti-colon cancer cell activity is associated with ceramide production.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26026677"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3543,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3544,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3545,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cediranib (AZD-2171) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 1001,
                "therapyName": "Cediranib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3546,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ofev (nintedanib) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3547,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 996,
                "therapyName": "Brivanib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3548,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 543,
                "profileName": "FGFR2 wild-type"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3705,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IMC-41A10 inhibited MST1R (RON) downstream signaling and migration of colon cancer cells in culture, and reduced tumor growth in MST1R-positive colorectal cancer xenograft models (PMID: 16982759).",
            "molecularProfile": {
                "id": 14931,
                "profileName": "MST1R over exp"
            },
            "therapy": {
                "id": 3253,
                "therapyName": "IMC-41A10",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4026,
                    "pubMedId": 16982759,
                    "title": "Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16982759"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3901,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) and Camptostar (irinotecan) synergistically suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R (PMID: 24042735) in xenograft models (PMID: 21325073).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 3396,
                "therapyName": "Gedatolisib + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 3639,
                    "pubMedId": 24042735,
                    "title": "Epigenetic and genetic features of 24 colon cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24042735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3902,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Camptostar (irinotecan) suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in xenograft models (PMID: 21325073, PMID: 16707468).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 1074,
                "therapyName": "Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 4272,
                    "pubMedId": 16707468,
                    "title": "KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16707468"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3903,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) and Camptothecin in combination synergistically enhanced Parp cleavage in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073).",
            "molecularProfile": {
                "id": 10711,
                "profileName": "KRAS G13D PIK3CA H1047R"
            },
            "therapy": {
                "id": 3398,
                "therapyName": "Camptothecin + Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4211,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CFI-400936 inhibited tumor growth in a human cell line xenograft model of colon cancer (PMID: 25043312).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3463,
                "therapyName": "CFI-400936",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4447,
                    "pubMedId": 25043312,
                    "title": "Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25043312"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4510,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YAP1 knockdown enhanced sensitivity of human colon cancer cell lines harboring BRAF V600E to Zelboraf (vemurafenib) in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 18268,
                "profileName": "BRAF V600E YAP1 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4512,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YAP1 knockdown enhanced sensitivity of human colon cancer cell lines harboring BRAF V600E to Mekinist (trametinib) in culture and reduced tumor growth in combination with Mekinist (trametinib) in BRAF V600E-mutant xenograft models (PMID: 25665005).",
            "molecularProfile": {
                "id": 18268,
                "profileName": "BRAF V600E YAP1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4514,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 blocked tumor growth of human colon cancer cells harboring BRAF V600E with targeted knockdown of YAP1 in xenografts (PMID: 25665005).",
            "molecularProfile": {
                "id": 18268,
                "profileName": "BRAF V600E YAP1 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4525,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3530,
                "therapyName": "Navitoclax + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4528,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1386,
                "therapyName": "Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4549,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring PTPRK-RSPO3 demonstrated inhibition of tumor growth and cell differentiation in xenograft models when treated with ETC-159 (PMID: 26257057).",
            "molecularProfile": {
                "id": 18336,
                "profileName": "PTPRK - RSPO3"
            },
            "therapy": {
                "id": 3534,
                "therapyName": "ETC-159",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4598,
                    "pubMedId": 26257057,
                    "title": "Wnt addiction of genetically defined cancers reversed by PORCN inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26257057"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4567,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AZD2811 nanoparticles resulted in tumor regression in colon cancer xenograft models (PMID: 26865565).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3547,
                "therapyName": "AZD2811",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4618,
                    "pubMedId": 26865565,
                    "title": "Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26865565"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4568,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and reduced tumor growth in xenograft models (PMID: 26715098).",
            "molecularProfile": {
                "id": 18590,
                "profileName": "KRAS mut PIK3CA wild-type"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4570,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and tumor growth in xenograft models (PMID: 26715098).",
            "molecularProfile": {
                "id": 18590,
                "profileName": "KRAS mut PIK3CA wild-type"
            },
            "therapy": {
                "id": 3548,
                "therapyName": "Buparlisib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4571,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18592,
                "profileName": "KRAS mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4572,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18592,
                "profileName": "KRAS mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4573,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18592,
                "profileName": "KRAS mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 3548,
                "therapyName": "Buparlisib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4574,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines harboring mutant KRAS and PIK3CA E545K demonstrated reduced sensitivity to Buparlisib (BKM120) induced growth inhibition in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18591,
                "profileName": "KRAS mut PIK3CA E545K"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4575,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18591,
                "profileName": "KRAS mut PIK3CA E545K"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4576,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18591,
                "profileName": "KRAS mut PIK3CA E545K"
            },
            "therapy": {
                "id": 3548,
                "therapyName": "Buparlisib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4644,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CPUY201112 reduced viability and induced apoptosis in a colon cancer cell line with wild-type TP53 in culture, and had a limited effect on a colon cancer cell line lacking TP53 (PMID: 26743233).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3589,
                "therapyName": "CPUY201112",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4657,
                    "pubMedId": 26743233,
                    "title": "CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4645,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells lacking TP53 had a decreased response to CPUY201112 in culture, when compared to colon cancer cells with wild-type TP53 (PMID: 26743233).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3589,
                "therapyName": "CPUY201112",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4657,
                    "pubMedId": 26743233,
                    "title": "CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743233"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4658,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing TTK S611G were resistant to inhibition by AZ3146 in culture (PMID: 26202014).",
            "molecularProfile": {
                "id": 18744,
                "profileName": "TTK S611G"
            },
            "therapy": {
                "id": 3117,
                "therapyName": "AZ3146",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4659,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, colon cancer cell lines expressing TTK I531M were resistant to inhibition by AZ3146 in culture (PMID: 26202014, PMID: 26364596).",
            "molecularProfile": {
                "id": 13159,
                "profileName": "TTK I531M"
            },
            "therapy": {
                "id": 3117,
                "therapyName": "AZ3146",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                },
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4660,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing TTK Y568C were resistant to inhibition by AZ3146 (PMID: 26202014).",
            "molecularProfile": {
                "id": 18745,
                "profileName": "TTK Y568C"
            },
            "therapy": {
                "id": 3117,
                "therapyName": "AZ3146",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4661,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing Ttk (Mps1) C604W were resistant to inhibition by AZ3146 (PMID: 26202014).",
            "molecularProfile": {
                "id": 18747,
                "profileName": "TTK C604W"
            },
            "therapy": {
                "id": 3117,
                "therapyName": "AZ3146",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4662,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing Ttk (Mps1) M600T were resistant to inhibition by AZ3146 (PMID: 26202014).",
            "molecularProfile": {
                "id": 18748,
                "profileName": "TTK M600T"
            },
            "therapy": {
                "id": 3117,
                "therapyName": "AZ3146",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4663,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing TTK S611G were sensitive to inhibition by NMS-P715 in culture (PMID: 26202014).",
            "molecularProfile": {
                "id": 18744,
                "profileName": "TTK S611G"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4664,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, colon cancer cell lines expressing TTK I531M were resistant to inhibition by NMS-P715 (PMID: 26202014, PMID: 26364596).",
            "molecularProfile": {
                "id": 13159,
                "profileName": "TTK I531M"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                },
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4665,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing TTK Y568C were resistant to inhibition by NMS-P715 in culture (PMID: 26202014).",
            "molecularProfile": {
                "id": 18745,
                "profileName": "TTK Y568C"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4666,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing Ttk (Mps1) C604W were resistant to inhibition by NMS-P715 (PMID: 26202014).",
            "molecularProfile": {
                "id": 18747,
                "profileName": "TTK C604W"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4667,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing Ttk (Mps1) M600T were resistant to inhibition by NMS-P715 (PMID: 26202014).",
            "molecularProfile": {
                "id": 18748,
                "profileName": "TTK M600T"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4668,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing TTK S611G were resistant to inhibition by CCT251455 in culture (PMID: 26202014).",
            "molecularProfile": {
                "id": 18744,
                "profileName": "TTK S611G"
            },
            "therapy": {
                "id": 3118,
                "therapyName": "CCT251455",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4669,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing TTK I531M were resistant to inhibition by CCT251455 (PMID: 26202014).",
            "molecularProfile": {
                "id": 13159,
                "profileName": "TTK I531M"
            },
            "therapy": {
                "id": 3118,
                "therapyName": "CCT251455",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4670,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing Ttk (Mps1) C604W were resistant to inhibition by CCT251455 (PMID: 26202014).",
            "molecularProfile": {
                "id": 18747,
                "profileName": "TTK C604W"
            },
            "therapy": {
                "id": 3118,
                "therapyName": "CCT251455",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4671,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing Ttk (Mps1) M600T were resistant to inhibition by CCT251455 (PMID: 26202014).",
            "molecularProfile": {
                "id": 18748,
                "profileName": "TTK M600T"
            },
            "therapy": {
                "id": 3118,
                "therapyName": "CCT251455",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4672,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing TTK Y568C were sensitive to inhibition by CCT251455 in culture (PMID: 26202014).",
            "molecularProfile": {
                "id": 18745,
                "profileName": "TTK Y568C"
            },
            "therapy": {
                "id": 3118,
                "therapyName": "CCT251455",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4673,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells expressing TTK S611G were resistant to inhibition by SNG12 in culture (PMID: 26202014).",
            "molecularProfile": {
                "id": 18744,
                "profileName": "TTK S611G"
            },
            "therapy": {
                "id": 3593,
                "therapyName": "SNG12",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4674,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing TTK Y568C were resistant to inhibition by SNG12 in culture (PMID: 26202014).",
            "molecularProfile": {
                "id": 18745,
                "profileName": "TTK Y568C"
            },
            "therapy": {
                "id": 3593,
                "therapyName": "SNG12",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4675,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing Ttk (Mps1) C604W were resistant to inhibition by SNG12 (PMID: 26202014).",
            "molecularProfile": {
                "id": 18747,
                "profileName": "TTK C604W"
            },
            "therapy": {
                "id": 3593,
                "therapyName": "SNG12",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4676,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing Ttk (Mps1) M600T were resistant to inhibition by SNG12 (PMID: 26202014).",
            "molecularProfile": {
                "id": 18748,
                "profileName": "TTK M600T"
            },
            "therapy": {
                "id": 3593,
                "therapyName": "SNG12",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4677,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing Ttk (Mps1) I531M were sensitive to inhibition by SNG12 in culture (PMID: 26202014).",
            "molecularProfile": {
                "id": 13159,
                "profileName": "TTK I531M"
            },
            "therapy": {
                "id": 3593,
                "therapyName": "SNG12",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4678,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing TTK S611G were resistant to inhibition by ONCOII in culture (PMID: 26202014).",
            "molecularProfile": {
                "id": 18744,
                "profileName": "TTK S611G"
            },
            "therapy": {
                "id": 3594,
                "therapyName": "ONCOII",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4679,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing TTK I531M were resistant to inhibition by ONCOII in culture (PMID: 26202014).",
            "molecularProfile": {
                "id": 13159,
                "profileName": "TTK I531M"
            },
            "therapy": {
                "id": 3594,
                "therapyName": "ONCOII",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4680,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing TTK Y568C were resistant to inhibition by ONCOII in culture (PMID: 26202014).",
            "molecularProfile": {
                "id": 18745,
                "profileName": "TTK Y568C"
            },
            "therapy": {
                "id": 3594,
                "therapyName": "ONCOII",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4681,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing Ttk (Mps1) C604W were resistant to inhibition by ONCOII (PMID: 26202014).",
            "molecularProfile": {
                "id": 18747,
                "profileName": "TTK C604W"
            },
            "therapy": {
                "id": 3594,
                "therapyName": "ONCOII",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4682,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines expressing Ttk (Mps1) M600T were resistant to inhibition by ONCOII (PMID: 26202014).",
            "molecularProfile": {
                "id": 18748,
                "profileName": "TTK M600T"
            },
            "therapy": {
                "id": 3594,
                "therapyName": "ONCOII",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3711,
                    "pubMedId": 26202014,
                    "title": "Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4692,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring TTK I531M was resistant to inhibition by Cpd-5 in culture (PMID: 26364596).",
            "molecularProfile": {
                "id": 13159,
                "profileName": "TTK I531M"
            },
            "therapy": {
                "id": 3465,
                "therapyName": "Cpd-5",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4696,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring TTK C604Y demonstrated resistance to inhibition by Cpd-5 in culture (PMID: 26364596).",
            "molecularProfile": {
                "id": 18826,
                "profileName": "TTK C604Y"
            },
            "therapy": {
                "id": 3465,
                "therapyName": "Cpd-5",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4697,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring TTK C604Y demonstrated resistance to inhibition by NMS-P715 in culture (PMID: 26364596).",
            "molecularProfile": {
                "id": 18826,
                "profileName": "TTK C604Y"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4702,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring TTK C604Y demonstrated resistance to inhibition by AZ3146 in culture (PMID: 26364596).",
            "molecularProfile": {
                "id": 18826,
                "profileName": "TTK C604Y"
            },
            "therapy": {
                "id": 3117,
                "therapyName": "AZ3146",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4706,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring TTK C604Y demonstrated resistance to inhibition by MPS1-IN-3 in culture (PMID: 26364596).",
            "molecularProfile": {
                "id": 18826,
                "profileName": "TTK C604Y"
            },
            "therapy": {
                "id": 3455,
                "therapyName": "MPS1-IN-3",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4711,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring TTK C604Y demonstrated sensitivity to inhibition by reversine in culture (PMID: 26364596).",
            "molecularProfile": {
                "id": 18826,
                "profileName": "TTK C604Y"
            },
            "therapy": {
                "id": 2327,
                "therapyName": "Reversine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4713,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring TTK C604Y demonstrated resistance to inhibition by MPI-0479605 in culture (PMID: 26364596).",
            "molecularProfile": {
                "id": 18826,
                "profileName": "TTK C604Y"
            },
            "therapy": {
                "id": 3458,
                "therapyName": "MPI-0479605",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4780,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KU-55933 induced cell cycle arrest and caspase activation in PTEN deficient human colon cancer cells in culture (PMID: 25870146).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 3116,
                "therapyName": "KU-55933",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4736,
                    "pubMedId": 25870146,
                    "title": "Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870146"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4799,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells treated with BX-320 demonstrated decreased cell growth in culture (PMID: 15772071).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3656,
                "therapyName": "BX-320",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4745,
                    "pubMedId": 15772071,
                    "title": "Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15772071"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4813,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells were sensitive to BX-912, resulting in cell growth inhibition in culture (PMID: 15772071).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3657,
                "therapyName": "BX-912",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4745,
                    "pubMedId": 15772071,
                    "title": "Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15772071"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5249,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY5 inhibited Stat3 signaling and growth in colon cancer cell lines exhibiting constitutive Stat3 activation in culture, and suppressed tumor growth in xenograft models (PMID: 26883202).",
            "molecularProfile": {
                "id": 17818,
                "profileName": "STAT3 act mut"
            },
            "therapy": {
                "id": 3798,
                "therapyName": "LY5",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4959,
                    "pubMedId": 26883202,
                    "title": "A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26883202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5463,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ch282-5 induced apoptosis and inhibited growth and migration of several human and mouse colon cancer cell lines in culture, and inhibited tumor growth and metastasis in xenograft models (PMID: 26515494).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3864,
                "therapyName": "Ch282-5",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5069,
                    "pubMedId": 26515494,
                    "title": "A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26515494"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5464,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ch282-5 and Eloxatin (oxaliplatin) inhibited cell growth in human and mouse colon cancer cell lines in culture, and the combination synergized to inhibit tumor growth in mouse colon cancer cell line xenograft models (PMID: 26515494).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3865,
                "therapyName": "Ch282-5 + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5069,
                    "pubMedId": 26515494,
                    "title": "A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26515494"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5519,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring KRAS G13D demonstrated increased sensitivity to Luminespib (AUY922) compared to cell lines with wild-type KRAS, resulting in decreased viability and increased apoptosis in culture and reduced tumor growth in xenograft models (PMID: 26832792).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5083,
                    "pubMedId": 26832792,
                    "title": "Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5605,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line expressing MAPK3 G186D demonstrated resistance to SCH772984 in culture as indicated by minimal inhibition of cell proliferation (PMID: 26832798).",
            "molecularProfile": {
                "id": 21296,
                "profileName": "MAPK3 G186D"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5122,
                    "pubMedId": 26832798,
                    "title": "Dissecting Therapeutic Resistance to ERK Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832798"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6459,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-3379 (KTN3379) had a modest inhibitory effect on tumor growth in xenograft models of colon cancer with high Erbb3 (Her3) expression and low Nrg1 (Hrg) expression (PMID: 26880266).",
            "molecularProfile": {
                "id": 23518,
                "profileName": "ERBB3 over exp NRG1 dec exp"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7084,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7085,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 24403,
                "profileName": "ERBB2 L866M"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7086,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3284,
                "profileName": "ERBB2 S310F"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11640,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response in a patient with ERBB2 (HER2) L755S, and 3 patients achieving stable disease for 24 weeks or more (PMID: 28679771).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9679,
                    "pubMedId": 28679771,
                    "title": "Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679771"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7087,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3151,
                "profileName": "ERBB2 L755S"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7088,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7089,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 24403,
                "profileName": "ERBB2 L866M"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7090,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3284,
                "profileName": "ERBB2 S310F"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7091,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3235,
                "profileName": "ERBB2 V842I"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7092,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7093,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3235,
                "profileName": "ERBB2 V842I"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7133,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of colon cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",
            "molecularProfile": {
                "id": 5943,
                "profileName": "NOTCH1 positive"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3325,
                    "pubMedId": null,
                    "title": "Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7150,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines demonstrated sensitivity to treatment with BGJ398 in culture, resulting in inhibition of FGFR4 phosphorylation and decreased cell growth (PMID: 24503538).",
            "molecularProfile": {
                "id": 2409,
                "profileName": "FGFR4 over exp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1057,
                    "pubMedId": 24503538,
                    "title": "Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24503538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7164,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465).",
            "molecularProfile": {
                "id": 24535,
                "profileName": "APC wild-type CTNNB1 wild-type"
            },
            "therapy": {
                "id": 4397,
                "therapyName": "Vantictumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6127,
                    "pubMedId": 22753465,
                    "title": "Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22753465"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7204,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer mouse model with loss of AIM2 demonstrated sensitivity to treatment with Triciribine (API-2), resulting in a decreased number of colon polyps and a reduced tumor load (PMID: 26107252).",
            "molecularProfile": {
                "id": 13317,
                "profileName": "AIM2 loss"
            },
            "therapy": {
                "id": 948,
                "therapyName": "Triciribine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3781,
                    "pubMedId": 26107252,
                    "title": "Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26107252"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7249,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 decreased viability of colon cancer cells with hypoxia-induced increased expression of Pim1 and Pim2 in culture (PMID: 27196781).",
            "molecularProfile": {
                "id": 24804,
                "profileName": "PIM1 over exp PIM2 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6257,
                    "pubMedId": 27196781,
                    "title": "PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196781"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7370,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS mutant colon cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4477,
                "therapyName": "Ponatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7395,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line treated with AZ628 demonstrated increased sensitivity when co-treated with CPI-455 in culture, resulting in decreased survival of cells, in particular the cells that eventually develop drug resistance (PMID: 27214401).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4487,
                "therapyName": "AZ628 + CPI-455",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6341,
                    "pubMedId": 27214401,
                    "title": "An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27214401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7524,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 50% (2/4) of patients with colon cancer (PMID: 26842236).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3314,
                "therapyName": "Irinotecan + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6398,
                    "pubMedId": 26842236,
                    "title": "Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26842236"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9947,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), as a monotherapy, is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7724,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human colon cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).",
            "molecularProfile": {
                "id": 2242,
                "profileName": "EGFR pos ERBB2 pos"
            },
            "therapy": {
                "id": 1048,
                "therapyName": "S-222611",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1835,
                    "pubMedId": 24837299,
                    "title": "Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24837299"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7840,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Trifluridine (FTD) resulted in Tp53-dependent cell-cycle arrest and decreased expression of CyclinB1 and Cdk1 in a Tp53-proficient colon cancer cancer cell line in culture (PMID: 25700705).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4586,
                "therapyName": "Trifluridine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6509,
                    "pubMedId": 25700705,
                    "title": "Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25700705"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7852,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Anetumab ravtansine inhibited survival of pancreatic carcinoma cells over expressing Msln (mesothelin) in culture and resulted in tumor regression in cell line and patient-derived xenograft models (PMID: 24714131).",
            "molecularProfile": {
                "id": 26076,
                "profileName": "MSLN over exp"
            },
            "therapy": {
                "id": 4593,
                "therapyName": "Anetumab ravtansine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6512,
                    "pubMedId": 24714131,
                    "title": "Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24714131"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7874,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 inhibited survival of colon cancer cell lines harboring BRAF V600E in cell culture and cell line xenograft models (PMID: 19276360).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7875,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells harboring BRAF N581Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",
            "molecularProfile": {
                "id": 23804,
                "profileName": "BRAF N581Y"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7877,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7880,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells harboring NRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7883,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type colon cancer cells harboring KRAS G13D in culture ann in cell line xenograft models (PMID: 19276360).",
            "molecularProfile": {
                "id": 26083,
                "profileName": "BRAF wild-type KRAS G13D"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8002,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 inhibited growth of colon cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 291,
                    "pubMedId": 18287029,
                    "title": "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18287029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8014,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a colon cancer cell line harboring KRAS G13D in culture (PMID: 27556948).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 4620,
                "therapyName": "APS-2-79 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6534,
                    "pubMedId": 27556948,
                    "title": "Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27556948"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8143,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WANT3 treatment resulted in suppression of cell invasion of colon cancer cells in culture (PMID: 27432794).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4640,
                "therapyName": "WANT3",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6553,
                    "pubMedId": 27432794,
                    "title": "The WASF3-NCKAP1-CYFIP1 Complex Is Essential for Breast Cancer Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432794"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8252,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type colon cancer cells in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8259,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type colon cancer cells in culture and in cell line xenograft models (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "KRT-232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8274,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-562271 inhibited PTK2 signaling, resulted in apoptosis and tumor regression in colon cancer cell line xenograft models (PMID: 18339875).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 2087,
                "therapyName": "PF-562271",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1919,
                    "pubMedId": 18339875,
                    "title": "Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18339875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8277,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 900 inhibited growth of colon cancer cell lines in culture, and inhibited tumor growth in colon cancer cell line xenograft models (PMID: 20935223).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 983,
                "therapyName": "AMG 900",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 46,
                    "pubMedId": 20935223,
                    "title": "Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20935223"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8280,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Apatinib (YN968D1) inhibited tumor growth in colon cancer cell line xenograft models (PMID: 21443688).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 986,
                "therapyName": "Apatinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 592,
                    "pubMedId": 21443688,
                    "title": "YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21443688"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8394,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navicixizumab (OMP-305B83) inhibited proliferation of endothelial cells in culture and demonstrated antitumor activity in vivo in multiple solid tumor types, including colon tumors (Mol Cancer Ther December 2015 14; C164).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2732,
                "therapyName": "Navicixizumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5881,
                    "pubMedId": null,
                    "title": "Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/C164.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8518,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26340,
                "profileName": "EZH2 pos KRAS G12D"
            },
            "therapy": {
                "id": 4746,
                "therapyName": "DZNeP + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8519,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26340,
                "profileName": "EZH2 pos KRAS G12D"
            },
            "therapy": {
                "id": 4747,
                "therapyName": "DZNeP + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8523,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Baicalein resulted in decreased growth of azoxymethane/dextran sodium sulfate-induced colon tumors in a MSH2-deficient mouse model (PMID: 27262172).",
            "molecularProfile": {
                "id": 16861,
                "profileName": "MSH2 inact mut"
            },
            "therapy": {
                "id": 4763,
                "therapyName": "Baicalein",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6673,
                    "pubMedId": 27262172,
                    "title": "A Novel Chemotherapeutic Agent to Treat Tumors with DNA Mismatch Repair Deficiencies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27262172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8532,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cells treated with HM-3 demonstrated reduced cell migration in culture and inhibition of tumor growth in xenograft models (PMID: 27633584).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4765,
                "therapyName": "HM-3",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6675,
                    "pubMedId": 27633584,
                    "title": "In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT\u2011116 xenograft model in nude mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27633584"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8907,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LF3 decreased expression of Wnt target genes and reduced tumor growth in colon cancer cell line xenograft models derived from cells with high levels of Wnt signaling (PMID: 26645562).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4846,
                "therapyName": "LF3",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6784,
                    "pubMedId": 26645562,
                    "title": "A Small-Molecule Antagonist of the \u03b2-Catenin/TCF4 Interaction Blocks the Self-Renewal of Cancer Stem Cells and Suppresses Tumorigenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645562"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9115,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified colon cancer cells in culture (PMID: 27550940).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6925,
                    "pubMedId": 27550940,
                    "title": "Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550940"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9152,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ASG-5ME inhibited tumor growth in colon cancer cell line xenograft and patient-derived xenograft (PDX) models (PMID: 27550944).",
            "molecularProfile": {
                "id": 26752,
                "profileName": "SLC44A4 positive"
            },
            "therapy": {
                "id": 4914,
                "therapyName": "ASG-5ME",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6935,
                    "pubMedId": 27550944,
                    "title": "The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550944"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9209,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines with KRAS codon 12 or 13 mutations demonstrated increased sensitivity to treatment with Luminespib (AUY922) in culture and in xenograft models (PMID: 26832792).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5083,
                    "pubMedId": 26832792,
                    "title": "Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9210,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Luminespib (AUY922) inhibited growth of colon cancer cell lines harboring KRAS G12V in culture (PMID: 26832792).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5083,
                    "pubMedId": 26832792,
                    "title": "Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9211,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Luminespib (AUY922) inhibited growth of a colon cancer cell line harboring KRAS G12D in culture (PMID: 26832792).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5083,
                    "pubMedId": 26832792,
                    "title": "Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9446,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IPI-549 inhibited tumor growth in cell line xenograft models of colon cancer through reducing the immune-suppressive tumor-associated myeloid cells (PMID: 27828943).",
            "molecularProfile": {
                "id": 26851,
                "profileName": "PIK3CG positive"
            },
            "therapy": {
                "id": 3363,
                "therapyName": "IPI-549",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7194,
                    "pubMedId": 27828943,
                    "title": "Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27828943"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9504,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NU7441 increased the sensitivity of colon cancer cell lines to radiotherapy, resulting in decreased cell survival in culture (PMID: 16707462).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5045,
                "therapyName": "NU7441 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7234,
                    "pubMedId": 16707462,
                    "title": "Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16707462"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9505,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NU7441 increased the sensitivity of colon cancer cell lines to Vepesid (etoposide), resulting in decreased cell survival in culture and reduced tumor growth in xenograft models (PMID: 16707462).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5046,
                "therapyName": "Etoposide + NU7441",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7234,
                    "pubMedId": 16707462,
                    "title": "Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16707462"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9506,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NU7441 increased sensitivity of colon cancer cell lines to Adriamycin (doxorubicin), resulting in reduced cell survival in culture (PMID: 16707462).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5047,
                "therapyName": "Doxorubicin + NU7441",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7234,
                    "pubMedId": 16707462,
                    "title": "Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16707462"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9548,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gemzar (gemcitabine) resulted in enhanced antitumor efficacy when combined with SRA737 (CCT245737) in a colon cancer cell line xenograft model (PMID: 27167172).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5070,
                "therapyName": "Gemcitabine + SRA737",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7267,
                    "pubMedId": 27167172,
                    "title": "Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27167172"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9854,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 inhibited phosphorylation of FGFR4 and increased sensitivity of colon cancer cell lines to Eloxatin (oxaliplatin), resulting in increased apoptosis in culture (PMID: 24503538).",
            "molecularProfile": {
                "id": 2409,
                "profileName": "FGFR4 over exp"
            },
            "therapy": {
                "id": 5256,
                "therapyName": "BGJ398 + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1057,
                    "pubMedId": 24503538,
                    "title": "Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24503538"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9944,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), as a monotherapy, is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10025,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 reduced Myc expression, induced cell-cycle arrest, and inhibited growth of a colon cancer cell line with FGFR2 amplification in culture (PMID: 27401245).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10057,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) resulted in some reduced cell growth in colon cancer cells harboring a BRAF mutation in culture (PMID: 27655129).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7992,
                    "pubMedId": 27655129,
                    "title": "MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27655129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10058,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring a KRAS mutation demonstrated sensitivity to AZ-TAK1 in culture, resulting in a 50% cell growth reduction (PMID: 27655129).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5359,
                "therapyName": "AZ-TAK1",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7992,
                    "pubMedId": 27655129,
                    "title": "MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27655129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10059,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of AZ-TAK1 and Selumetinib (AZD6244) resulted in an additive effect in colon cancer cells harboring KRAS mutant in culture, demonstrating a 90% growth reduction (PMID: 27655129).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5360,
                "therapyName": "AZ-TAK1 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7992,
                    "pubMedId": 27655129,
                    "title": "MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27655129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10060,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring KRAS G12V demonstrated sensitivity to AZ-TAK1 in culture, resulting in inhibition of cell growth (PMID: 27655129).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 5359,
                "therapyName": "AZ-TAK1",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7992,
                    "pubMedId": 27655129,
                    "title": "MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27655129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10258,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant colon cancer (PMID: 26140595).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10259,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of BRAF mutant colon cancer (PMID: 26140595).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10292,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MPT0E028 decreased proliferation and increased apoptosis in a colon cancer cell line in culture and inhibited tumor growth in a colon cancer cell line xenograft model (PMID: 22928010).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2658,
                "therapyName": "MPT0E028",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8257,
                    "pubMedId": 22928010,
                    "title": "Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22928010"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10293,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pracinostat (SB939) inhibited proliferation of colon cancer cell lines in culture, and increased histone H3 acetylation and inhibited tumor growth in a colon cancer cell line xenograft model (PMID: 20197387).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1758,
                "therapyName": "Pracinostat",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8261,
                    "pubMedId": 20197387,
                    "title": "SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20197387"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10294,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Quisinostat (JNJ-26481585) induced apoptosis and inhibited proliferation of colon cancer cell lines in culture, and inhibited tumor growth in a colon cancer cell line xenograft model (PMID: 19861438).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3004,
                "therapyName": "Quisinostat",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3420,
                    "pubMedId": 19861438,
                    "title": "JNJ-26481585, a novel \"second-generation\" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19861438"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10298,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a colon cancer patient harboring PIK3CA E545K was sensitive to LY2780301, demonstrating stable disease for approximately 125 days (PMID: 25902900).",
            "molecularProfile": {
                "id": 2421,
                "profileName": "PIK3CA E545K"
            },
            "therapy": {
                "id": 800,
                "therapyName": "LY2780301",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3473,
                    "pubMedId": 25902900,
                    "title": "A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25902900"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10316,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chiauranib (CS2164) inhibited tumor growth in a colon cancer cell line xenograft model (PMID: 28004478).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1998,
                "therapyName": "Chiauranib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8299,
                    "pubMedId": 28004478,
                    "title": "CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28004478"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10331,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-TNKS656 inhibited tumor growth in a patient-derived xenograft model of metastatic colon cancer expressing high levels of nuclear CTNNB1 (Beta-catenin) and FOXO3 (PMID: 26224873).",
            "molecularProfile": {
                "id": 27360,
                "profileName": "CTNNB1 over exp FOXO3 over exp"
            },
            "therapy": {
                "id": 5467,
                "therapyName": "NVP-TNKS656",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8313,
                    "pubMedId": 26224873,
                    "title": "Tankyrase Inhibition Blocks Wnt/\u03b2-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26224873"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10333,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of NVP-TNKS656 and Triciribine (API-2) inhibited tumor growth in Triciribine (API-2)-resistant patient-derived xenograft (PDX) models of colon cancer with high nuclear CTNNB1 (Beta-catenin) levels (PMID: 26224873).",
            "molecularProfile": {
                "id": 26160,
                "profileName": "CTNNB1 over exp"
            },
            "therapy": {
                "id": 5469,
                "therapyName": "NVP-TNKS656 + Triciribine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8313,
                    "pubMedId": 26224873,
                    "title": "Tankyrase Inhibition Blocks Wnt/\u03b2-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26224873"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10670,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colon cancer patient harboring KRAS A59T demonstrated sensitivity to the combination treatment of Vectibix (panitumumab) and FOLFIRI, which resulted in an objective response of a 36% decrease according to RECIST (PMID: 28404754).",
            "molecularProfile": {
                "id": 862,
                "profileName": "KRAS A59T"
            },
            "therapy": {
                "id": 5573,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Panitumumab",
                "synonyms": "Panitumumab + FOLFIRI"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8729,
                    "pubMedId": 28404754,
                    "title": "Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28404754"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10795,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CVX-060 inhibited tumor growth in a colon cancer cell line xenograft model (PMID: 21233403).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5618,
                "therapyName": "CVX-060",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8820,
                    "pubMedId": 21233403,
                    "title": "Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21233403"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10796,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of CVX-060 and Sutent (suntinib) resulted in increased tumor growth inhibition compared to either agent alone in a colon cancer cell line xenograft model (PMID: 21233403).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5622,
                "therapyName": "CVX-060 + Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8820,
                    "pubMedId": 21233403,
                    "title": "Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21233403"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10797,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of CVX-060 and Nexavar (sorafenib) resulted in increased tumor growth inhibition compared to either agent alone in a colon cancer cell line xenograft model (PMID: 21233403).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5623,
                "therapyName": "CVX-060 + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8820,
                    "pubMedId": 21233403,
                    "title": "Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21233403"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10798,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of CVX-060 and Avastin (bevacizumab) resulted in increased tumor growth inhibition compared to either agent alone in a colon cancer cell line xenograft model (PMID: 21233403).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5624,
                "therapyName": "Bevacizumab + CVX-060",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8820,
                    "pubMedId": 21233403,
                    "title": "Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21233403"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10821,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGP-15 induced apoptosis and inhibited growth of colon cancer cells in culture and in cell line xenograft models (PMID: 22661288).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2537,
                "therapyName": "BGP-15",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2481,
                    "pubMedId": 22661288,
                    "title": "Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22661288"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10931,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer mouse model harboring an APC mutation demonstrated decreased polyp formation and decreased cell proliferation when treated with the EP4 antagonist, E7046 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B198).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5694,
                "therapyName": "E7046",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8941,
                    "pubMedId": null,
                    "title": "Abstract B198: Pharmacological profile of the PGE2 EP4 receptor antagonist E7046",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B198.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10941,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of E7046 and radiotherapy resulted in 9 out of 12 tumor free colon cancer mouse models and increased the number of T-cells infiltrating the tumor (International Journal of Rad Onc, 2016, 96;2, S128).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5699,
                "therapyName": "E7046 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8946,
                    "pubMedId": null,
                    "title": "Combination of a Novel EP4 Antagonist E7046 and Radiation Therapy Promotes Anti-tumor Immune Response and Tumor Rejection in Preclinical Tumor Models",
                    "url": "http://www.redjournal.org/article/S0360-3016(16)30638-1/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10963,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with colon cancer harboring a KRAS mutation demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5739,
                "therapyName": "OPB-111077",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8960,
                    "pubMedId": null,
                    "title": "Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B118.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11052,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colon cancer patient harboring BRAF V600E and TP53 Q192K demonstrated a partial response when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 28514312).",
            "molecularProfile": {
                "id": 27902,
                "profileName": "BRAF V600E TP53 Q192K"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9046,
                    "pubMedId": 28514312,
                    "title": "Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28514312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11383,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLH1 deficient colon cancer cell lines were sensitive to KU60648 in culture, demonstrating decreased cell viability and reduced colony formation (PMID: 28224663).",
            "molecularProfile": {
                "id": 25004,
                "profileName": "MLH1 loss"
            },
            "therapy": {
                "id": 5967,
                "therapyName": "KU60648",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9237,
                    "pubMedId": 28224663,
                    "title": "Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28224663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11384,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MSH6 deficient colon cancer cells did not respond to treatment with KU60648 in culture (PMID: 28224663).",
            "molecularProfile": {
                "id": 7744,
                "profileName": "MSH6 loss"
            },
            "therapy": {
                "id": 5967,
                "therapyName": "KU60648",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9237,
                    "pubMedId": 28224663,
                    "title": "Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28224663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11385,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KU60648 combined with irradiation resulted in enhanced sensitivity compared to KU60648 alone in MSH3 deficient colon cancer cells in culture, demonstrating reduced colony formation (PMID: 28224663).",
            "molecularProfile": {
                "id": 27976,
                "profileName": "MSH3 loss"
            },
            "therapy": {
                "id": 5968,
                "therapyName": "KU60648 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9237,
                    "pubMedId": 28224663,
                    "title": "Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28224663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11386,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a MLH1 and MSH3 deficient colon cancer cell line demonstrated sensitivity to treatment with KU60648 in culture, showing decreased cell viability and reduced colony formation (PMID: 28224663).",
            "molecularProfile": {
                "id": 27977,
                "profileName": "MLH1 loss MSH3 loss"
            },
            "therapy": {
                "id": 5967,
                "therapyName": "KU60648",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9237,
                    "pubMedId": 28224663,
                    "title": "Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28224663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11847,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CCT244747 and Camptosar (irinotecan) slowed tumor growth to a greater degree than treatment with either agent alone in colon cancer xenograft models (PMID: 22929806).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6171,
                "therapyName": "CCT244747 + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6590,
                    "pubMedId": 22929806,
                    "title": "CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22929806"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11848,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CCT244747 and Gemzar (gemcitabine) slowed tumor growth to a greater degree than treatment with either agent alone and decreased Chek1 phosphorylation in colon cancer cell line xenograft models (PMID: 22929806).",
            "molecularProfile": {
                "id": 26229,
                "profileName": "CHEK1 positive"
            },
            "therapy": {
                "id": 6172,
                "therapyName": "CCT244747 + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6590,
                    "pubMedId": 22929806,
                    "title": "CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22929806"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11893,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PKF118-310 inhibited Kdm4a activity and induced apoptosis in colon cancer cells (PMID: 27767379).",
            "molecularProfile": {
                "id": 28335,
                "profileName": "KDM4A positive"
            },
            "therapy": {
                "id": 2397,
                "therapyName": "PKF118-310",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9770,
                    "pubMedId": 27767379,
                    "title": "Identification and characterization of PKF118-310 as a KDM4A inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27767379"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11894,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PKF118-310 inhibited Kdm4a activity and induced apoptosis in TP53-deleted colon cancer cells (PMID: 27767379).",
            "molecularProfile": {
                "id": 28336,
                "profileName": "KDM4A pos TP53 del"
            },
            "therapy": {
                "id": 2397,
                "therapyName": "PKF118-310",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9770,
                    "pubMedId": 27767379,
                    "title": "Identification and characterization of PKF118-310 as a KDM4A inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27767379"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11930,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic colon cancer harboring BRAF V600E demonstrated mixed radiographic response with slight progression in some locations and stable disease in other locations for 7 months following treatment with the combination of Nexavar (sorafenib) and Erbitux (cetuximab) (PMID: 23792568).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6209,
                "therapyName": "Cetuximab + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9915,
                    "pubMedId": 23792568,
                    "title": "Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23792568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12587,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) is not indicated for use in colon cancer patients with KRAS exon 2 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 27386,
                "profileName": "KRAS exon2"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12728,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Ensituximab (NEO-102) demonstrated safety and preliminary efficacy, resulting in stable disease in 42% (5/12) of patients with refractory colon or pancreatic cancer (PMID: 27449137; NCT01040000).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6607,
                "therapyName": "Ensituximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10658,
                    "pubMedId": 27449137,
                    "title": "A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27449137"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12765,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line deficient in TP53 demonstrated increased sensitivity to sequential treatment with SN-38 and CHIR-124 compared to cells with wild-type TP53, resulting in increased apoptosis and micronucleation in culture (PMID: 17255282).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 6628,
                "therapyName": "CHIR-124 + SN-38",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10687,
                    "pubMedId": 17255282,
                    "title": "CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17255282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13006,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) is not indicated for use in colon cancer patients with KRAS exon 3 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 27387,
                "profileName": "KRAS exon3"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13007,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) is not indicated for use in colon cancer patients with KRAS exon 4 mutation (NCCN.org).",
            "molecularProfile": {
                "id": 27388,
                "profileName": "KRAS exon4"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13008,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) is not indicated for use in colon cancer patients with KRAS exon 2 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 27386,
                "profileName": "KRAS exon2"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13009,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) is not indicated for use in colon cancer patients with KRAS exon 3 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 27387,
                "profileName": "KRAS exon3"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13010,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) is not indicated for use in colon cancer patients with KRAS exon 4 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 27388,
                "profileName": "KRAS exon4"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13011,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) is not indicated for use in colon cancer patients with NRAS exon 3 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 27390,
                "profileName": "NRAS exon3"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13012,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab) is not indicated for use in colon cancer patients with NRAS exon 4 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 27391,
                "profileName": "NRAS exon4"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13013,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 3 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 27390,
                "profileName": "NRAS exon3"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13014,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 4 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 27391,
                "profileName": "NRAS exon4"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13794,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of colon cancer cells harboring FGFR2 amplification and FGFR2-COL14A1 fusion in culture and in cell line xenograft models (PMID: 27627808).",
            "molecularProfile": {
                "id": 28932,
                "profileName": "FGFR2 - COL14A1 FGFR2 amp"
            },
            "therapy": {
                "id": 2900,
                "therapyName": "Derazantinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11276,
                    "pubMedId": 27627808,
                    "title": "Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27627808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13917,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acquisition NTRK1 G667C conferred resistance to Rozlytrek (entrectinib) in a colon cancer cell line harboring TPM3-NTRK1 in xenograft models (PMID: 29463555).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11364,
                    "pubMedId": 29463555,
                    "title": "Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29463555"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14095,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SKLB-23bb treatment resulted in antitumor efficacy in colon cancer cells, demonstrating decreased colony formation in vitro and inhibition of tumor growth in cell line xenograft models (PMID: 29610282).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7019,
                "therapyName": "SKLB-23bb",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11452,
                    "pubMedId": 29610282,
                    "title": "SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29610282"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14364,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Vitrakvi (larotrectinib) treatment resulted in partial response in 50% (2/4) and stable disease in 50% (2/4) of patients with colon cancer harboring NTRK1 fusions (PMID: 29466156, Annals of Oncology, Volume 29, Issue suppl_5; NCT02122913, NCT02637687, and NCT02576431).",
            "molecularProfile": {
                "id": 2904,
                "profileName": "NTRK1 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                },
                {
                    "id": 11608,
                    "pubMedId": null,
                    "title": "Activity of larotrectinib in patients with TRK fusion GI malignancies",
                    "url": "https://academic.oup.com/annonc/article/29/suppl_5/mdy149.019/5039356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15068,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) arrested tumor growth in cell line xenograft models of colon cancer overexpressing Igf2bp3 (PMID: 28193878).",
            "molecularProfile": {
                "id": 30727,
                "profileName": "IGF2BP3 over exp"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12604,
                    "pubMedId": 28193878,
                    "title": "THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28193878"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15140,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell line xenograft models demonstrated tumor regression when treated with IT-141 (PMID: 22187652).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7423,
                "therapyName": "IT-141",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12681,
                    "pubMedId": 22187652,
                    "title": "IT-141, a Polymer Micelle Encapsulating SN-38, Induces Tumor Regression in Multiple Colorectal Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22187652"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15272,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, NTRK1 G595R and NTRK1 F589L were identified at disease progression in a patient with colon cancer harboring TPM3-NTRK1 treated with Vitrakvi (larotrectinib) (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 30934,
                "profileName": "TPM3 - NTRK1 NTRK1 F589L NTRK1 G595R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15306,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, NTRK1 G595R was identified at disease progression in a patient with colon cancer harboring LMNA-NTRK1 treated with Vitrakvi (larotrectinib) (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 27367,
                "profileName": "LMNA - NTRK1 NTRK1 G595R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15345,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FN-1501 induced cell-cycle arrest decreased proliferation in a colon cancer cell line in culture (PMID: 29357250).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7564,
                "therapyName": "FN-1501",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13099,
                    "pubMedId": 29357250,
                    "title": "Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29357250"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15420,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARID1A-deficient colon cancer xenograft models demonstrated an increased response to treatment with an anti-PD-L1 antibody compared to controls (PMID: 29736026).",
            "molecularProfile": {
                "id": 8724,
                "profileName": "ARID1A loss"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11347,
                    "pubMedId": 29736026,
                    "title": "ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29736026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16002,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of colon cancer cells harboring KRAS Q61L in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 1863,
                "profileName": "KRAS Q61L"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16013,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of colon cancer cell lines harboring KRAS G12V in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16021,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of colon cancer cells harboring KRAS G12D in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16480,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MC180295 decreased growth of colon cancer cell lines in culture, and reduced tumor growth rate and improved survival in colon cancer cell line xenograft models (PMID: 30454645).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8055,
                "therapyName": "MC180295",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14528,
                    "pubMedId": 30454645,
                    "title": "Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30454645"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16620,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JSH-150 inhibited proliferation of a colon cancer cell line in culture (PMID: 30253346).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8108,
                "therapyName": "JSH-150",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14640,
                    "pubMedId": 30253346,
                    "title": "Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30253346"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16705,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of NOX-A12 and an anti-PD-1 antibody demonstrated increased efficacy over either agent alone in a mouse colon cancer model, resulting in responses in 5/8 mice, compared to 2/8 with the anti-PD-1 antibody alone (PMID: 28963140).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8153,
                "therapyName": "NOX-A12 + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14733,
                    "pubMedId": 28963140,
                    "title": "Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28963140"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16975,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 8360,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab",
                "synonyms": "Panitumumab + FOLFOXIRI"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16976,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFOXIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2184,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFIRINOX"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16981,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) in combination with Perjeta (pertuzumab) is included in guidelines as second-line therapy for advanced or metastatic colon cancer patients with ERBB2 amplification and KRAS, BRAF wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 35566,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16982,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) in combination with Perjeta (pertuzumab) is included in guidelines as second-line therapy for advanced or metastatic colon cancer patients with ERBB2 amplification and NRAS, BRAF wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 35567,
                "profileName": "BRAF wild-type ERBB2 amp NRAS wild-type"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16983,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) in combination with Tykerb (lapatinib) is included in guidelines as second-line therapy for advanced or metastatic colon cancer patients with ERBB2 amplification and NRAS, BBRAF wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 35567,
                "profileName": "BRAF wild-type ERBB2 amp NRAS wild-type"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16984,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) in combination with Tykerb (lapatinib) is included in guidelines as second-line therapy for advanced or metastatic colon cancer patients with ERBB2 amplification and KRAS, BRAF wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 35566,
                "profileName": "BRAF wild-type ERBB2 amp KRAS wild-type"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16985,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16986,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with Camptosar (irinotecan), is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 4138,
                "therapyName": "Irinotecan + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16987,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Opdivo (nivolumab) is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients with high microsatellite instability, MSI-H (NCCN.org).",
            "molecularProfile": {
                "id": 29714,
                "profileName": "MSI high"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16988,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients with high microsatellite instability, MSI-H (NCCN.org).",
            "molecularProfile": {
                "id": 29714,
                "profileName": "MSI high"
            },
            "therapy": {
                "id": 1627,
                "therapyName": "Ipilimumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16989,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Keytruda (pembrolizumab) is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients with high microsatellite instability, MSI-H (NCCN.org).",
            "molecularProfile": {
                "id": 29714,
                "profileName": "MSI high"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17021,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFOX, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1986,
                "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab",
                "synonyms": "Panitumumab + FOLFOX"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17022,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFOX, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2182,
                "therapyName": "Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Cetuximab + FOLFOX"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17023,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Erbitux (cetuximab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17024,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vectibix (panitumumab), in combination with FOLFIRI, is included in guidelines for advanced or metastatic left-sided colon tumors with BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org).",
            "molecularProfile": {
                "id": 29053,
                "profileName": "BRAF wild-type KRAS wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 5573,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Panitumumab",
                "synonyms": "Panitumumab + FOLFIRI"
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17077,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Debio 1347 treatment resulted in a partial response with 49.5% reduction of tumor size and 66% decrease of DUSP6 score in a patient with colon cancer harboring FGFR1 amplification and FGFR2 fusion (PMID: 30745300; NCT01948297).",
            "molecularProfile": {
                "id": 32330,
                "profileName": "FGFR2 fusion FGFR1 amp"
            },
            "therapy": {
                "id": 1014,
                "therapyName": "Debio 1347",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15194,
                    "pubMedId": 30745300,
                    "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30745300"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17171,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Debio 1347 treatment resulted in a partial response in 2 patient with colon cancer harboring FGFR2-INA (PMID: 30745300; NCT01948297).",
            "molecularProfile": {
                "id": 32356,
                "profileName": "FGFR2 - INA"
            },
            "therapy": {
                "id": 1014,
                "therapyName": "Debio 1347",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15194,
                    "pubMedId": 30745300,
                    "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30745300"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17465,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic colon cancer harboring BRAF K601E developed progressive disease after 6 weeks of Mektovi (binimetinib) and Vectibix (panitumumab) combination treatment, MAP2K1 V211D was identified as a co-occuring mutation in the biopsy from the new metastasis site (PMID: 31227518).",
            "molecularProfile": {
                "id": 32620,
                "profileName": "BRAF K601E MAP2K1 V211D"
            },
            "therapy": {
                "id": 8513,
                "therapyName": "Binimetinib + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15507,
                    "pubMedId": 31227518,
                    "title": "V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17468,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP955 inhibited Rsk and Erk phosphorylation, and resulted in 30% tumor regression in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).",
            "molecularProfile": {
                "id": 32620,
                "profileName": "BRAF K601E MAP2K1 V211D"
            },
            "therapy": {
                "id": 8514,
                "therapyName": "MAP855",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15507,
                    "pubMedId": 31227518,
                    "title": "V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17471,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) did not inhibit Rsk and Erk phosphorylation, and had no effect on tumor growth in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).",
            "molecularProfile": {
                "id": 32620,
                "profileName": "BRAF K601E MAP2K1 V211D"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15507,
                    "pubMedId": 31227518,
                    "title": "V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17472,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) and Erbitux (cetuximab) combination did not inhibit Rsk and Erk phosphorylation, and had no effect on tumor growth in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).",
            "molecularProfile": {
                "id": 32620,
                "profileName": "BRAF K601E MAP2K1 V211D"
            },
            "therapy": {
                "id": 8515,
                "therapyName": "Binimetinib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15507,
                    "pubMedId": 31227518,
                    "title": "V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17584,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines harboring KRAS A146T demonstrated growth rates similar to cells expressing wild-type KRAS when treated with SHP099 in culture (PMID: 30952657).",
            "molecularProfile": {
                "id": 1441,
                "profileName": "KRAS A146T"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15680,
                    "pubMedId": 30952657,
                    "title": "Tissue-Specific Oncogenic Activity of KRASA146T.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952657"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17585,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines harboring KRAS G12D demonstrated growth rates similar to cells expressing wild-type KRAS when treated with SHP099 in culture (PMID: 30952657).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15680,
                    "pubMedId": 30952657,
                    "title": "Tissue-Specific Oncogenic Activity of KRASA146T.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952657"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18743,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an anti-PD-1 inhibitor combined with DSP-0509 inhibited tumor growth in a syngeneic mouse model of colon cancer (Cancer Res July 1 2018 (78) (13 Supplement) 4726).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8828,
                "therapyName": "DSP-0509 + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16398,
                    "pubMedId": null,
                    "title": "Novel intravenous injectable TLR7 agonist, DSP-0509, synergistically enhanced antitumor immune responses in combination with anti-PD-1 antibody",
                    "url": "https://cancerres.aacrjournals.org/content/78/13_Supplement/4726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18881,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing colon cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17286,
                "profileName": "MLH1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18882,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing colon cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17287,
                "profileName": "MSH2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18883,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing colon cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17288,
                "profileName": "MSH6 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18884,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing colon cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17289,
                "profileName": "PMS2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19002,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 inhibited Erk1/2 phosphorylation and viability of colon cancer cell lines harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19009,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 did not inhibit Erk1/2 phosphorylation and viability of KRAS wild-type colon cancer cells harboring TPM3-NTRK1 in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 33812,
                "profileName": "TPM3 - NTRK1 KRAS wild-type"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19010,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 did not inhibit Erk1/2 phosphorylation and viability of KRAS wild-type colon cancer cells harboring BRAF V600E in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 21304,
                "profileName": "BRAF V600E KRAS wild-type"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19232,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-06840003 inhibited tumor growth in syngeneic mouse models of colon cancer (PMID: 30232146).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8945,
                "therapyName": "PF-06840003",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16799,
                    "pubMedId": 30232146,
                    "title": "Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30232146"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19251,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AsiDNA inhibited survival of colon cancer cell lines in culture (PMID: 27559053).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8967,
                "therapyName": "AsiDNA",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16843,
                    "pubMedId": 27559053,
                    "title": "Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27559053"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19252,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AsiDNA treatment led to increased sensitivity to Lynparza (olaparib), resulting in decreased survival in colon cancer cell lines in culture (PMID: 27559053).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8968,
                "therapyName": "AsiDNA + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16843,
                    "pubMedId": 27559053,
                    "title": "Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27559053"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19310,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, introduction of CDK11B G579S into a colon cancer cell line conferred resistance to OTS964 in culture (PMID: 31511426).",
            "molecularProfile": {
                "id": 34027,
                "profileName": "CDK11B G579S"
            },
            "therapy": {
                "id": 5259,
                "therapyName": "OTS964",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16920,
                    "pubMedId": 31511426,
                    "title": "Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31511426"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19325,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring KRAS G13D did not demonstrate sensitivity to MRTX849 treatment in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 7769,
                "therapyName": "MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19474,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a BRCA2 knockout colon cancer cell line did not confer sensitivity to AZD7648 treatment compared to BRCA2-positive cells in culture (PMID: 31699977).",
            "molecularProfile": {
                "id": 11671,
                "profileName": "BRCA2 del"
            },
            "therapy": {
                "id": 8900,
                "therapyName": "AZD7648",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19497,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line with MAP3K1-deficiency via knockdown was sensitive to Selumetinib (AZD6244), demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34163,
                "profileName": "MAP3K1 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19498,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line with MAP2K4-deficiency via knockdown was sensitive to Selumetinib (AZD6244), demonstrating decreased cell proliferation in culture and reduced tumor volume in cell line xenograft models (PMID: 29795445).",
            "molecularProfile": {
                "id": 34164,
                "profileName": "MAP2K4 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19503,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line with MAP3K1-deficiency via knockdown was sensitive to Mekinist (trametinib), demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34163,
                "profileName": "MAP3K1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19506,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line with MAP3K1-deficiency via knockdown was sensitive to SCH772984, demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34163,
                "profileName": "MAP3K1 dec exp"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19509,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line with MAP2K4-deficiency via knockdown was sensitive to Mekinist (trametinib), demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34164,
                "profileName": "MAP2K4 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19512,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line with MAP2K4-deficiency via knockdown was sensitive to SCH772984, demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34164,
                "profileName": "MAP2K4 dec exp"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19515,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line with MAP3K1-deficiency via knockdown was sensitive to Mektovi (binimetinib), demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34163,
                "profileName": "MAP3K1 dec exp"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19518,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line with MAP2K4-deficiency via knockdown was sensitive to Mektovi (binimetinib), demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34164,
                "profileName": "MAP2K4 dec exp"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19521,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer xenograft models with wild-type MAP2K4 and MAP3K1 did not respond to treatment with Selumetinib (AZD6244) (PMID: 29795445).",
            "molecularProfile": {
                "id": 34182,
                "profileName": "MAP2K4 wild-type MAP3K1 wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19897,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Buparlisib (BKM120) combination treatment synergistically inhibited growth of a colon cancer cell line harboring KRAS G12C in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 9251,
                "therapyName": "Buparlisib + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19951,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NR4A1 induced apoptosis and inhibited viability of a NR4A1-expressing colon cancer cell line in culture (PMID: 30926635).",
            "molecularProfile": {
                "id": 34736,
                "profileName": "NR4A1 positive"
            },
            "therapy": {
                "id": 9258,
                "therapyName": "BI1071",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17623,
                    "pubMedId": 30926635,
                    "title": "BI1071, a Novel Nur77 Modulator, Induces Apoptosis of Cancer Cells by Activating the Nur77-Bcl-2 Apoptotic Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30926635"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20293,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BOS172722 treatment resulted in increased apoptosis and decreased growth of a colon cancer cell line in culture (PMID: 31575759).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9311,
                "therapyName": "BOS172722",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17794,
                    "pubMedId": 31575759,
                    "title": "High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575759"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20474,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colon cancer patient harboring KRAS G13D and TP53 C242fs demonstrated a partial response with a 30% decrease in lesions by RECIST when treated with the combination therapy of Kineret (anakinra), Avastin (bevacizumab), Mekinist (trametinib), Eloxatin (oxaliplatin), and Adrucil (fluorouracil) (PMID: 31782524).",
            "molecularProfile": {
                "id": 35185,
                "profileName": "KRAS G13D TP53 C242fs"
            },
            "therapy": {
                "id": 9365,
                "therapyName": "Anakinra + Bevacizumab + Fluorouracil + Oxaliplatin + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17853,
                    "pubMedId": 31782524,
                    "title": "Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31782524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21311,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with colon cancer harboring NCOA4-RET did not respond to treatment with Cometriq (Cabometyx, cabozantinib) in culture, demonstrating cell viability levels similar to control treatment (PMID: 30210625).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 12496,
                    "pubMedId": 30210625,
                    "title": "NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30210625"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21312,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with colon cancer harboring NCOA4-RET did not respond to treatment with Nexavar (sorafenib) in culture, demonstrating cell viability levels similar to control treatment (PMID: 30210625).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 12496,
                    "pubMedId": 30210625,
                    "title": "NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30210625"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21313,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with colon cancer harboring NCOA4-RET did not respond to treatment with Ibrance (palbociclib) in culture, demonstrating cell viability levels similar to control treatment (PMID: 30210625).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 12496,
                    "pubMedId": 30210625,
                    "title": "NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30210625"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21314,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with colon cancer harboring NCOA4-RET were sensitive to treatment with Caprelsa (vandetanib) in culture, demonstrating decreased cell viability and inhibition of Akt and Erk phosphorylation (PMID: 30210625).",
            "molecularProfile": {
                "id": 10515,
                "profileName": "NCOA4 - RET"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12496,
                    "pubMedId": 30210625,
                    "title": "NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30210625"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01274624",
            "title": "Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                },
                {
                    "id": 2099,
                    "therapyName": "Bevacizumab + Reolysin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01730118",
            "title": "Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1404,
                    "therapyName": "HER2 Vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01966289",
            "title": "SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1949,
                    "therapyName": "Guadecitabine",
                    "synonyms": null
                },
                {
                    "id": 2977,
                    "therapyName": "GVAX colorectal cancer vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02014909",
            "title": "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2054,
                    "therapyName": "CDX-3379",
                    "synonyms": null
                },
                {
                    "id": 2063,
                    "therapyName": "CDX-3379 + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 2064,
                    "therapyName": "CDX-3379 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 2061,
                    "therapyName": "CDX-3379 + Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 2062,
                    "therapyName": "CDX-3379 + Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02041481",
            "title": "MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2217,
                    "therapyName": "Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Binimetinib  + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT02448173",
            "title": "A Multicenter Study of Active Specific Immunotherapy With OncoVax\u00ae in Patients With Stage II Colon Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02508077",
            "title": "FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                },
                {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02628535",
            "title": "Safety Study of MGD009 in B7-H3-expressing Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6631,
                    "therapyName": "MGD009",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02784795",
            "title": "A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4374,
                    "therapyName": "Cisplatin + Gemcitabine + LY3039478",
                    "synonyms": null
                },
                {
                    "id": 4375,
                    "therapyName": "Carboplatin + Gemcitabine + LY3039478",
                    "synonyms": null
                },
                {
                    "id": 4372,
                    "therapyName": "LY3023414 + LY3039478",
                    "synonyms": null
                },
                {
                    "id": 4373,
                    "therapyName": "Abemaciclib + LY3039478",
                    "synonyms": null
                },
                {
                    "id": 4371,
                    "therapyName": "LY3039478 + Taladegib",
                    "synonyms": null
                },
                {
                    "id": 2958,
                    "therapyName": "LY3039478",
                    "synonyms": null
                },
                {
                    "id": 1069,
                    "therapyName": "LY3023414",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02824042",
            "title": "Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4594,
                    "therapyName": "Anetumab ravtansine + Itraconazole",
                    "synonyms": null
                },
                {
                    "id": 4593,
                    "therapyName": "Anetumab ravtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02834052",
            "title": "Pembrolizumab + Poly-ICLC in MRP Colon Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4458,
                    "therapyName": "Pembrolizumab + Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02860780",
            "title": "A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4587,
                    "therapyName": "Prexasertib + Ralimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02980029",
            "title": "Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3611,
                    "therapyName": "TVB-2640",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03127098",
            "title": "QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6239,
                    "therapyName": "ALT-803 + ETBX-011",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03157128",
            "title": "Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)ET Activation (LIBRETTO-001)er",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5702,
                    "therapyName": "Selpercatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03199586",
            "title": "Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7358,
                    "therapyName": "NP-G2-044",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03207867",
            "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4741,
                    "therapyName": "PBF-509 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03317119",
            "title": "Trametinib and TAS-102 in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6393,
                    "therapyName": "Trametinib + trifluridine/tipiracil hydrochloride",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03631641",
            "title": "Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03711058",
            "title": "Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6899,
                    "therapyName": "Copanlisib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03827967",
            "title": "Trial of PalloV-CC in Colon Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9689,
                    "therapyName": "PalloV-CC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03829410",
            "title": "Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7881,
                    "therapyName": "Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + PCM-075",
                    "synonyms": "Bevacizumab  + PCM-075 + FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT03872947",
            "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8046,
                    "therapyName": "Pembrolizumab + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8078,
                    "therapyName": "Carboplatin + Gemcitabine + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8047,
                    "therapyName": "Imiquimod + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8079,
                    "therapyName": "Paclitaxel + Ramucirumab + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8045,
                    "therapyName": "Nivolumab + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8077,
                    "therapyName": "Cisplatin + Gemcitabine + TRK-950",
                    "synonyms": null
                },
                {
                    "id": 8043,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin + TRK-950",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03919292",
            "title": "Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8245,
                    "therapyName": "Divalproex sodium + Neratinib",
                    "synonyms": null
                }
            ]
        }
    ]
}